Hybrid antibiotics based oxazolidinone-quinolone.

Compounds of formula (I) (see formula) in which A is an alkylene group, an alkenylene group, an alkynylene group, a heteroalkylene group, a cycloalkylene group, a heterocycloalkylene group, an arylene group or a heteroarylene group all of which they may be substituted; Q is CR 4; X is CR 7 or N; Y is CR 6 or N; n is 1, 2 or 3; m is 1, 2 or 3; R 1 is H, F, Cl, Br, I, OH, NH2, an alkyl group or a heteroalkyl group; R 2 is H, F or Cl; R 3 is H, an alkyl group, an alkenyl group, an alkynyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group; all these groups may be substituted with one, two or more halogen atoms or amino groups; R 4 is hydroxy, a group of formula OPO3R September 2 or OSO3R 10 or a heteroalkyl group having at least one OH, NH2, SO3R 10, PO3R September 2 or COOH group or an ester of a naturally occurring amino acid or derivative thereof, wherein the groups R 9 independently are H, alkyl, cycloalkyl, aryl or aralkyl, and wherein R 10 is H, alkyl, cycloalkyl, aryl or aralkyl; R 5 is selected from the following groups: (See formulas) R 6 is H, F, Cl or OMe; R 7 is H, F, Cl, OH, NH2, an alkyl group substituted or unsubstituted, or a substituted or unsubstituted, or R 3 and R 7 heteroalkyl group may be bonded via an alkylene group, a alquenilenico group or a heteroalquilenico, or it may be a part of a cycloalkylene or heterocicloalquilenico group, if R 3 is not H and R 7 is not H, F, OH, NH2 or Cl; and R 8 is a heteroalkyl group of C1 - 6, a heteroarilalquilico group, a heteroalquilarilico group, or a group heteroalquilheteroarilico; or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.